Department of Obstetrics and Gynaecology, University of Auckland, National Womens Hospital, Private Bag 92 189, Auckland 3, New Zealand.
Hum Reprod. 2010 Sep;25(9):2281-9. doi: 10.1093/humrep/deq187. Epub 2010 Jul 22.
There are different funding arrangements for fertility treatments between New Zealand (NZ) and Australia. In NZ, there are two options for patients accessing treatment: either meeting specified criteria for age, no smoking and BMI for publicly funding or funding their own treatment. This differs from Australia, which has no explicit eligibility criteria restricting access to fertility treatment. An analysis of assisted reproductive technology (ART) in Australia and NZ was undertaken to consider the impact of these different funding approaches.
Data were extracted from the Australian and New Zealand Assisted Reproduction Database between 2004 and 2007. A total of 116 111 autologous fresh cycles were included.
In Australia, more cycles were in women aged 40 years or older compared with those in NZ (23.5 versus 16.0%, P < 0.01). Single embryo transfer was more common in NZ than that in Australia, in women < 35 years of age (75.1 versus 59.6%, P < 0.01). In women <35 years, the crude rates of clinical pregnancy (37.5 versus 31.2%, P < 0.01) and live delivery (31.6 versus 26%, P < 0.01) following fresh ART cycles were significantly higher in NZ than that in Australia. These differences in outcomes persisted in older age groups.
The purpose of the criteria used in NZ to access public funding for fertility treatments is to optimize pregnancy outcomes. This approach has resulted in a healthier population of women undergoing treatment and may explain the improved pregnancy outcomes seen in NZ couples who undergo fertility treatments.
新西兰（NZ）和澳大利亚在生育治疗方面有不同的资金安排。在 NZ，患者有两种选择：要么符合特定的年龄、不吸烟和 BMI 标准，以获得公共资金资助，要么自费治疗。这与澳大利亚不同，澳大利亚没有明确的资格标准限制生育治疗的获取。对澳大利亚和 NZ 的辅助生殖技术（ART）进行了分析，以考虑这些不同资金方法的影响。
从 2004 年至 2007 年，从澳大利亚和新西兰辅助生殖数据库中提取数据。共纳入 116111 例自体新鲜周期。
在澳大利亚，40 岁及以上女性的周期数多于 NZ（23.5%比 16.0%，P < 0.01）。在年龄<35 岁的女性中，NZ 比澳大利亚更常见单胚胎移植（75.1%比 59.6%，P < 0.01）。在年龄<35 岁的女性中，新鲜 ART 周期后的临床妊娠率（37.5%比 31.2%，P < 0.01）和活产率（31.6%比 26%，P < 0.01）均明显高于澳大利亚。这些结果差异在年龄较大的组中仍然存在。
NZ 用于获得公共资金资助生育治疗的标准旨在优化妊娠结局。这种方法导致接受治疗的女性人群更健康，这可能解释了 NZ 夫妇接受生育治疗后妊娠结局改善的原因。
